| 000 | 01597 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250511205710.0 | ||
| 264 | 0 | _c19910828 | |
| 008 | 199108s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/1097-0142(19910815)68:4<730::aid-cncr2820680411>3.0.co;2-c _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLong, H J | |
| 245 | 0 | 0 |
_aA phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. _h[electronic resource] |
| 260 |
_bCancer _cAug 1991 |
||
| 300 |
_a730-2 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMenogaril |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNogalamycin _xadverse effects |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aLaurie, J A | |
| 700 | 1 | _aWieand, H S | |
| 700 | 1 | _aEdmonson, J H | |
| 700 | 1 | _aLevitt, R | |
| 700 | 1 | _aKrook, J E | |
| 700 | 1 | _aAbu-Ghazaleh, S | |
| 773 | 0 |
_tCancer _gvol. 68 _gno. 4 _gp. 730-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1097-0142(19910815)68:4<730::aid-cncr2820680411>3.0.co;2-c _zAvailable from publisher's website |
| 999 |
_c1836443 _d1836443 |
||